How much has Amgen raised?
Amgen is not venture-backed. As of June 2026 it was a public company trading as Nasdaq: AMGN, with $36.8B 2025 of 2025 revenue scale and mature access to public-company financing tools.
- Public status
- Nasdaq: AMGN
- Revenue
- $36.8B 2025
- Funding type
- Public markets
- Disclosed rounds
- Not VC disclosed
- First raised
- Public-company history
- Seller signal
- Enterprise healthcare buyer
Amgen's capital history
Amgen's capital history is public-company funding, operating cash flow, acquisitions, and market access rather than startup rounds.
- 1980Company foundedAmgen begins the business that later scales into a public healthcare company.
- Public listingNasdaq: AMGN public-market accessPublic equity and debt-market access replace startup-style venture rounds as the relevant capital lens.
- Portfolio eraPortfolio expansionAcquisitions, divestitures, internal R&D, and manufacturing investments become important capital-allocation tools.
- 2025$36.8B 2025 revenue scaleAmgen reported 2025 total revenues of $36.8 billion, up 10% from 2024.
- Jun 2026Nasdaq: AMGN public companyAmgen remains a public enterprise healthcare buyer with mature procurement controls.
How much has Amgen raised in total?
Amgen does not have a meaningful current venture-funding total. The company should be evaluated through public equity, operating cash flow, debt capacity, acquisitions, divestitures, partnerships, and retained earnings rather than Seed, Series A, or late-stage venture rounds.
Who are Amgen's investors?
The relevant investors are public-market shareholders, index funds, active healthcare investors, bondholders where applicable, and internal capital allocators. Their focus is durable revenue, margins, cash conversion, pipeline or product execution, regulatory risk, reimbursement exposure, and management's ability to deploy capital at attractive returns.
Why does Amgen's valuation move?
Amgen's valuation moves with growth, margins, cash flow, clinical or regulatory milestones, procedure or prescription trends, test volume, reimbursement, pricing pressure, product cycles, supply reliability, litigation, acquisitions, and investor confidence in management's outlook. Healthcare buyers can still spend during turbulent markets, but approvals become more tied to measurable savings and risk control.
Is Amgen profitable, and will it IPO?
Amgen is already public. Profitability should be assessed from its filings and earnings releases rather than IPO readiness; the practical question is how much cash and management attention can be allocated to new vendors, systems, facilities, clinical programs, commercial expansion, or productivity work.
What does Amgen's funding mean if you sell into them?
The company has enterprise-scale budget capacity, but procurement is mature and evidence-driven. Sellers should expect security review, compliance review, legal negotiation, business-unit sponsorship, and a requirement to prove value in patient outcomes, operating efficiency, revenue capture, supply reliability, cybersecurity, data quality, or risk reduction.
As of June 2026.Sources:Amgen 2025 resultsAmgen annual reportsNasdaq: AMGN market data
Amgen — frequently asked questions
